Review Articles Concerning Pulmonary Vascular Disease

Congenital and acquired pulmonary vein stenosis

Larry A. Latson, Lourdes R. PrietoCleveland Clinic FoundationUnited States CirculationCirculation 2007; 115: 103-108DOI: 10.1161/CIRCULATIONAHA.106.646166 AbstractNo Abstract Available CategorySegmental Pulmonary Venous Disease. Without a Focus on Pulmonary HypertensionSurgical and Catheter-mediated Interventions for Pulmonary Vascular DiseaseDiagnostic Testing for Pulmonary Vascular Disease. Non-invasive TestingDiagnostic Testing for Pulmonary Vascular Disease. Invasive TestingReview Articles Concerning Pulmonary Vascular Disease Age Focus: Pediatric Pulmonary Vascular Disease […]

Congenital and acquired pulmonary vein stenosis Read More »

The emerging roles of SUMOylation in pulmonary diseases

Xuyang Zheng, Lingqiao Wang, Zhen Zhang, Huifang TangThe Affiliated Hangzhou First People’s Hospital, Zhejiang Respiratory Drugs Research Laboratory and Zhejiang University School of Medicine. China Molecular MedicineMol Med 2023; 29: DOI: 10.1186/s10020-023-00719-1 AbstractSmall ubiquitin-like modifier mediated modification (SUMOylation) is a critical post-translational modification that has a broad spectrum of biological functions, including genome replication and repair,

The emerging roles of SUMOylation in pulmonary diseases Read More »

Imaging of pulmonary venous developmental anomalies

Jonathan R. Dillman, Sai G. Yarram, Ramiro J. HernandezUniversity of Michigan Health System and C. S. Mott Children’s Hospital.United States American Journal of RoentgenologyAJR Am J Roentgenol 2009; 192: 1272-1285DOI: 10.2214/AJR.08.1526 AbstractObjective: The purpose of this article is to review pulmonary venous embryology and to present the imaging findings of a variety of pulmonary venous developmental anomalies,

Imaging of pulmonary venous developmental anomalies Read More »

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

Lucilla Piccari, Brian Allwood, Katerina Antoniou, Jonathan H. Chung, Paul M. Hassoun, Sylvia M. Nikkho, Rajan Saggar, Oksana A. Shlobin, Patrizio Vitulo, Steven D. Nathan, Stephen John WortHospital del Mar. Stellenbosch University and Tygerberg Hospital. University of Crete School of Medicine. The University of Chicago. Johns Hopkins University. Bayer AG. University of California Los Angeles

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension Read More »

Inhaled nitric oxide use in newborns

Souvik Mitra, Gabriel AltitCanadian Paediatric Society.Canada Paediatrics and Child HealthPaediatr Child Health 2023; 28: 119-127DOI: 10.1093/pch/pxac107 AbstractInhaled nitric oxide (iNO), a selective pulmonary vasodilator, is used as a therapeutic modality in infants with hypoxemic respiratory failure (HRF) associated with persistent pulmonary hypertension of the newborn (PPHN). iNO should ideally be initiated following echocardiographic confirmation of PPHN.

Inhaled nitric oxide use in newborns Read More »

Management of pulmonary arterial hypertension during pregnancy

Kaushiga Krishnathasan, Andrew Constantine, Isma Rafiq, Ana Barradas Pires, Hannah Douglas, Laura C. Price, Konstantinos DimopoulosRoyal Brompton Hospital and Royal Brompton & Harefield Hospitals. Imperial College. St Thomas’ Hospital. King’s College.United Kingdom Expert Review of Respiratory MedicineExpert Rev Respir Med 2023; 17: 413-423DOI: 10.1080/17476348.2023.2210838 AbstractIntroduction: Pulmonary arterial hypertension (PAH) is defined as a mean pulmonary artery pressure

Management of pulmonary arterial hypertension during pregnancy Read More »

Pulmonary Hypertension in Chronic Lung Diseases: What Role Do Radiologists Play?

Adele Valentini, Paola Franchi, Giuseppe Cicchetti, Gaia Messana, Greta Chiffi, CeciliaStrappa, Lucio Calandriello, Annemiliadel Ciello, Alessandra Farchione, Lorenzo Preda, Anna Rita LariciFondazione IRCCS Policlinico San Matteo. G. Mazzini Hospital. Fondazione Policlinico Universitario. University of Pavia. Università Cattolica del Sacro Cuore. Italy DiagnosticsDiagnostics 2023; 13: DOI: 10.3390/diagnostics13091607 AbstractPulmonary hypertension (PH) is a pathophysiological disorder, defined by a

Pulmonary Hypertension in Chronic Lung Diseases: What Role Do Radiologists Play? Read More »

Unique Pulmonary Hypertensive Vascular Diseases Associated with Heart and Lung Developmental Defects

Hidekazu Ishida, Jun Maeda, Keiko Uchida, Hiroyuki YamagishiOsaka University Graduate School of Medicine. Tokyo Metropolitan Children’s Medical Center. Keio University of Medicine and Health Center.Japan Journal of Cardiovascular Development and DiseaseJ Cardiovasc Dev Dis 2023; DOI: 10.3390/jcdd10080333 AbstractAlthough pediatric pulmonary hypertension (PH) shares features and mechanisms with adult PH, there are also some significant differences between

Unique Pulmonary Hypertensive Vascular Diseases Associated with Heart and Lung Developmental Defects Read More »

MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment

Łukasz Wołowiec, Martyna Medlewska, Joanna Osiak, Anna Wołowiec, Elzbieta Grzésk3 , Albert Jásniak, Grzegorz GrzéskNicolaus Copernicus University.Poland International Journal of Molecular SciencesInt J Mol Sci 2023; 24: DOI: 10.3390/ijms24119735 AbstractPulmonary hypertension (PH) is characterized by a progressive increase in pulmonary arterial pressure and pulmonary vascular resistance. In a short time, it leads to right ventricular failure

MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment Read More »

Pulmonary vascular disease as a complication of pediatric congenital heart diseases

Julie Wacker, Raphael Joye, Leon Genecand, Frederic Lador, Maurice BeghettiGeneva University Hospitals. Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique.Switzerland Translational PediatricsTransl Pediatr 2023; 12: 1041-1052DOI: 10.21037/tp-23-64 AbstractCongenital and acquired heart diseases can cause pulmonary hypertension (PH) in children, either by increasing pulmonary blood flow (PBF), left atrial pressure (LAp), and/or pulmonary vascular resistance (PVR).

Pulmonary vascular disease as a complication of pediatric congenital heart diseases Read More »

Scroll to Top